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cal analyses are conducted to assess the signiﬁcance of
trends.
RESULTS: Up to 155,000 type-2 diabetes patients are
identiﬁed in each year. Insulin was used by 21.6% in
1997, decreasing to 20.3% in 2000. During the same
period, the use of insulin-alone declined from 12.6% to
9.9%, while the use of insulin and OADs in the same year
increased from 9.0% to 10.4%. Patients receiving insulin,
compared to patients treated with OADs or no drug
therapy, were more likely to have signiﬁcant diabetic
comorbidities (54.4% vs. 26.1% and 21.5%), and more
doctor visits per year (9.2 vs.7.4 and 6.8).
CONCLUSIONS: It appears that the use of insulin
therapy for treating type 2 diabetes patients has declined
slightly over the past four years (1997–2000), possibly in
response to the introduction of new oral antihyper-
glycemic drugs and the widespread promotion of treat-
ment guidelines. It is likely that the use of insulin
combination therapies has increased, while the use of
insulin monotherapy has decreased over the same time
period.
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OBJECTIVE: To assess patient perspective on hypo-
glycemia in patients with type 2 diabetes taking oral
hypoglycemic agents (OHAs).
METHODS: A questionnaire was developed to explore
the subjects’ perception and knowledge of hypoglycemia,
including frequency and severity of symptoms. We also
assessed the potential relationship of hypoglycemia to
OHAs. Thirty-one study subjects with type 2 diabetes and
at least 30 years of age responded to advertisements to
participate in this study. Patients were distributed in three
groups according to age and previous experience 
of hypoglycemia: group 1: older patients with hypo-
glycemia experience, group 2: patients without previous
hypoglycemia and group 3: adults with previous hypo-
glycemia. Patients completed a questionnaire and then
took part in a moderated focus group.
RESULTS: Eight subjects in group 1 (mean age 66.4 ± 2.8
years old) and 12 patients in group 3 (mean age 52.7 ±
6.4 years old) reported experiencing hypoglycemia; while
12 patients in group 2 (mean age 56.8 ± 6.8 years old)
reported, “not experiencing hypoglycemia” in the past.
Patients completed the questionnaire and then partici-
pated in a moderated focus group. Less than 25% of
group 1 and 2 patients recognized the symptoms of hypo-
glycemia. Approximately 27% of patients in group 2
experienced these symptoms but none recognized they
were manifestations of hypoglycemia and 18% reported
that they experienced trembling very often or always.
None of the subjects connected these symptoms with their
antidiabetic medications. All patients in group 1 seemed
to be surprised that OHAs have side effects. Approxi-
mately 25% of patients gave a wrong deﬁnition of hypo-
glycemia in their questionnaires.
CONCLUSIONS: There seems to be a large information
gap about hypoglycemia. Patient and provider education
is needed to help patients to understand what hypo-
glycemia is or recognize the symptoms of hypoglycemia.
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OBJECTIVES: The objective of this study was to deter-
mine if routinely collected administrative claims data
could be used to effectively predict what segment of a
population of patients with type 2 diabetes mellitus (type
2 DM) would progress to insulin as part of their drug
regimen.
METHODS: To determine the time until a patient with
type 2 DM starts insulin, deﬁned as survival time, we used
the PHREG procedure of SAS. This procedure uses Cox’s
proportional hazards model in order to estimate survival
functions for diabetic patients. Based on the number of
medications in the patients’ regimen, eleven models were
developed to predict the number of patients in a cohort
expected to start insulin therapy over the two-year study
period. The models were also used to identify the patients
most likely to start insulin therapy and to estimate their
probability. Split sample design was used to gauge the
predictive ability of the models.
RESULTS: In the monotherapy cohort model, the average
of the absolute difference between the predicted and
actual number of patients starting insulin each month was
0.965, with the maximum error for any month being 4.1
patients (an average of 27 patients started insulin per
month). 27.03% and 24.12% of the patients that went
on insulin within six months or two years respectively
were in the top 10% in terms of risk. In comparison,
3.3% and 3.53% of the patients that went on insulin
within six months or two years respectively were found
to be in the bottom 10% in terms of risk.
CONCLUSIONS: This study demonstrates that survival
models can be used to predict and identify patients with
type 2 DM who will require insulin as part of their treat-
ment regimen. As a result, it is possible to develop tools
based on these models that can be used by practitioners
to assist in patient care.
